Financial Performance - Total revenues for Q3 2025 were $49.69 billion, with premium and service revenues at $44.90 billion, representing a 22% increase from $36.90 billion in Q3 2024[2][11] - Adjusted diluted EPS for Q3 2025 was $0.50, benefiting from a low adjusted effective tax rate of 0.6% compared to 22.9% in Q3 2024[4][11] - The company updated its full year 2025 adjusted diluted EPS forecast to at least $2.00, an increase of $0.25 from previous guidance[4][10] - Total revenues for the three months ended September 30, 2025, increased to $49,690 million, up from $42,023 million in the same period of 2024, representing a growth of 18.9%[33] - Premium revenues for the nine months ended September 30, 2025, reached $127,578 million, compared to $106,784 million in 2024, reflecting a year-over-year increase of 19.4%[33] - Net loss attributable to Centene Corporation for the three months ended September 30, 2025, was $6,631 million, compared to a net income of $713 million in the same period of 2024[33] Expenses and Liabilities - The GAAP diluted loss per share was $(13.50), primarily due to a non-cash goodwill impairment of $6.7 billion[4][11] - The adjusted selling, general and administrative expenses for the nine months ended September 30, 2025, were $9,522 million, compared to $9,081 million for the same period in 2024, reflecting an increase of approximately 4.9%[23] - The total GAAP selling, general and administrative expenses for the three months ended September 30, 2025, were $3,145 million, compared to $3,057 million for the same period in 2024[23] - Total liabilities increased to $61,032 million as of September 30, 2025, from $55,935 million at December 31, 2024, reflecting a rise of 9.4%[31] - The company reported an impairment charge of $6,743 million for the three months ended September 30, 2025, compared to no impairment in the same period of 2024[33] Membership and Market Position - Total Medicaid membership decreased to 12.71 million from 13.07 million year-over-year, while Marketplace membership increased to 5.83 million from 4.50 million[5][11] - Total commercial membership increased to 6,276,000 in Q3 2025, up 7.1% from 4,927,900 in Q3 2024[37] - The company serves over 1 in 15 individuals across the nation, focusing on under-insured and uninsured individuals through government-sponsored and commercial healthcare programs[25] Operational Efficiency - The health benefits ratio (HBR) for Medicaid was 93.4%, reflecting a 40 basis point benefit from a retroactive revenue adjustment[4][11] - The Health Benefits Ratio (HBR) is calculated as medical costs divided by premium revenues, which is a key metric for assessing operational efficiency[24] - The medical claims liability balance increased to $21,493 million as of September 30, 2025, up from $17,995 million on September 30, 2024[38] - The incurred medical claims for the current period totaled $150,533 million, while total paid claims amounted to $144,535 million[38] - The Health Benefits Ratio (HBR) for Medicaid was 93.4% in Q3 2025, slightly up from 93.1% in Q3 2024[37] Cash Flow and Capital Structure - Cash flow provided by operations for Q3 2025 was $1.36 billion, primarily driven by the timing of claims and other payments[11] - Cash flows from operating activities for the nine months ended September 30, 2025, were $4,651 million, significantly higher than $741 million in the same period of 2024[35] - Total current assets as of September 30, 2025, amounted to $44,062 million, up from $37,999 million at December 31, 2024, indicating a growth of 15.4%[31] - Cash and cash equivalents at the end of the period were $17,185 million, compared to $14,650 million at the end of September 2024, showing an increase of 10.4%[35] - Total debt stood at $17.6 billion, with a debt-to-capital ratio of 45.5% as of September 30, 2025[4][9] Employee and Corporate Recognition - The company was recognized in the 2025 Forbes® America's Best Employers for Company Culture™ list, highlighting high employee satisfaction[3] - The number of employees increased to 60,900 in Q3 2025 from 60,300 in Q2 2025[37] Regulatory and Strategic Considerations - The company anticipates potential impacts from changes in federal or state laws or regulations, which could affect its government-sponsored healthcare programs[27] - The company emphasizes the importance of maintaining adequate premium levels and controlling future medical and administrative costs to ensure financial stability[28] - Favorable development in prior periods resulted in a reduction of approximately $106 million in premium revenues due to minimum HBR and return of premium programs[39]

For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ ____________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ____________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31826 _________________ ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Centene Corporation (CNC) is expected to report a loss of $0.21 per share for Q3 2025, with revenues projected at $47.62 billion, reflecting a year-over-year revenue growth of 13.3% despite a significant earnings decline of 113% [1][2][6]. Financial Performance - The earnings estimate for Q3 2025 has remained stable over the past 60 days, indicating a year-over-year plunge in earnings, while revenue projections suggest growth [2][3]. - For the full year 2025, Centene's revenue is estimated at $190.45 billion, representing a 16.8% increase year-over-year, but the EPS is projected to decrease by 76.4% [3][4]. Membership and Revenue Trends - Total commercial memberships are expected to increase by 26.6% year-over-year, with Medicare PDP memberships also showing nearly 17% growth [6][7]. - However, total membership is projected to decline by 2.2% year-over-year, primarily due to decreases in Medicaid and Medicare memberships [8]. - The consensus estimate for service revenues indicates a 7.2% decline from the previous year, while investment and other income is expected to fall by 11.7% [9]. Cost and Expense Outlook - Centene's medical costs are anticipated to remain high, with the health benefits ratio expected to rise to 93%, indicating a reduced portion of premiums available after claims [10]. - Total operating expenses are projected to increase by more than 15% in Q3, which may negatively impact the bottom line [10].

Core Insights - The Mid Cap Value portfolio experienced a gain of 1.70% in Q3 2025, underperforming compared to the Russell Midcap® Value Index, which increased by 6.18% [2] Performance Analysis - The portfolio's performance was primarily affected by stock selection, indicating that specific investment choices did not yield favorable results compared to the benchmark [2]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1]. Group 1: Industry Overview - The performance of the five largest health insurers in the U.S. by market capitalization is discussed, specifically mentioning UnitedHealth Group Incorporated and CVS Health [1]. - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts for investment decisions and buy/sell ratings [1]. Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over five years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the Haggerston BioHealth investing group [1].

Core Insights - Molina Healthcare reported disappointing third-quarter results, leading to a decline in stock prices for Centene Corporation and Oscar Health Inc. [1] - The company’s adjusted earnings per share for Q3 were $1.84, significantly lower than $6.01 from the previous year and below the consensus estimate of $3.90 [1] Financial Performance - Molina Healthcare's consolidated medical care ratio (MCR) for Q3 2025 increased to 92.6%, up from 89.2% year-over-year [2] - The MCR breakdown includes 92.0% for Medicaid, 93.6% for Medicare, and 95.6% for Marketplace [2] Future Guidance - For fiscal 2025, Molina Healthcare expects adjusted earnings of $14 per share, lower than the consensus of $18.65 and previous guidance of over $19 [3] - The company raised its 2025 sales guidance from $44 billion to $44.5 billion, slightly above the consensus of $44.39 billion [3] Cost Trends - The updated guidance reflects higher medical cost trends across all segments, particularly in the Marketplace, which is anticipated to persist through the end of the year [4] - Molina forecasts a 2025 MCR of 91.3%, with specific expectations of 91.5% for Medicaid, 91.3% for Medicare, and 89.7% for Marketplace, compared to earlier expectations of 90.2% overall [4] Upcoming Earnings Reports - Centene is set to release its Q3 2025 financial results on October 29, with analysts estimating an adjusted loss of 14 cents and sales of $47.75 billion [5] - Oscar Health will report its Q3 2025 results on November 6, with an expected adjusted loss of 56 cents and sales of $3.08 billion [5] Market Reaction - Following Molina Healthcare's report, Oscar Health's stock fell by 9.74% to $18.39, while Centene's stock decreased by 6.61% [7]

The health care sector has taken an enormous pounding in the last few months, which few active investors missed. Medical expense ratios skyrocketed across the board, leading to much lower earnings, despite solid revenue growth in most companies. EPSHi! I'm a passionate investor who has been researching publically traded companies for over 6 years. My primary focus is on identifying great businesses at reasonable prices and holding them for the long term but I also dive into trend following strategies from t ...

Core Insights - The health care sector has experienced significant challenges recently, with medical expense ratios increasing sharply, resulting in lower earnings despite revenue growth in many companies [1] Group 1: Industry Overview - The health care sector has faced a substantial downturn in the last few months, impacting investor sentiment [1] - Medical expense ratios have skyrocketed across the board, indicating rising costs that are affecting profitability [1] - Despite solid revenue growth in most companies, the increase in medical expenses has led to much lower earnings [1]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Landscape - Wall Street is investing hundreds of billions into AI, but there is a pressing concern regarding the energy supply needed to sustain this growth [2] - AI data centers, such as those powering large language models, consume energy equivalent to that of small cities, indicating a significant strain on global power grids [2] - The company in focus is positioned to capitalize on the rising demand for electricity, which is becoming the most valuable commodity in the digital age [3][8] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, benefiting from the surge in energy demand driven by AI advancements [4][5] - It possesses critical nuclear energy infrastructure assets and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7][8] - The company is debt-free and has a substantial cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] Market Positioning - The company has an equity stake in another prominent AI venture, providing investors with indirect exposure to multiple growth opportunities in the AI sector [9] - It is trading at a low valuation of less than 7 times earnings, making it an attractive investment option in the context of AI and energy [10][11] - The company is poised to benefit from the onshoring trend and increased U.S. LNG exports, aligning with the "America First" energy policy [6][7][14] Future Outlook - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12] - The overall narrative emphasizes that investing in AI is not just about financial returns but also about participating in a transformative technological revolution [15][19]